Litcius/Paper detail

Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid

J Pruessmann, Wiebke Pruessmann, M Holtsche, Birgit Linnemann, Christoph M. Hammers, Nathalie van Beek, Detlef Zillikens, Erik Berg Schmidt, Christian D. Sadik

2021Acta Dermato Venereologica11 citationsDOIOpen Access PDF

Abstract

Massive recruitment of eosinophils into the dermis is a hallmark of bullous pemphigoid pathogenesis. Identifying the chemoattractant(s) guiding eosinophils into the skin in bullous pemphigoid is a prerequisite to thera-peutic targeting of eosinophil recruitment. Galectin -9 is a potent chemoattractant for eosinophils, but its potential role in bullous pemphigoid is unknown. The aim of this study was to determine the expression levels of galectin-9 in serum and skin of patients with bullous pemphigoid. Galectin-9 levels were significantly elevated in serum of patients with bullous pemphigoid compared with age- and sex-matched controls, but did not correlate with disease activity assessed with the Bullous Pemphigoid Disease Area Index. Galectin-9 expression was also increased in lesional skin of patients with bullous pemphigoid, and was expressed predominantly in eosinophils, neutrophils and keratinocytes. In conclusion, these results support the notion that galectin-9 may play a role in the patho-genesis of bullous pemphigoid.

Topics & Concepts

Bullous pemphigoidMedicinePemphigoidPathogenesisEosinophilDermatologyImmunologyGalectinAntibodyAsthmaAutoimmune Bullous Skin DiseasesGalectins and Cancer BiologyCoagulation, Bradykinin, Polyphosphates, and Angioedema
Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid | Litcius